Institute for Clinical and Economic Review, Boston, Massachusetts.
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora.
J Manag Care Spec Pharm. 2020 Jun;26(6):782-785. doi: 10.18553/jmcp.2020.26.6.782.
Funding for this summary was contributed by Arnold Ventures, Commonwealth Fund, California Health Care Foundation, National Institute for Health Care Management (NIHCM), New England States Consortium Systems Organization, Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, Kaiser Foundation Health Plan, and Partners HealthCare to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, America's Health Insurance Plans, Anthem, Allergan, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Cambia Health Services, CVS, Editas, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, Health Partners, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, and United Healthcare. Pearson is employed by ICER; Synnott was employed by ICER at the time of this report. Ollendorf, Campbell, and McQueen received grants from ICER for work on this review. Ollendorf also reports advisory board, consulting, and other fees from Sarepta Therapeutics, DBV Technologies, EMD Serono, Gerson Lehman Group, The CEA Registry Sponsors, Autolus, Analysis Group, Amgen, AbbVie, Cytokinetics, Aspen Institute/University of Southern California, and University of Colorado, unrelated to this review.
本摘要的资助由 Arnold Ventures、Commonwealth Fund、加利福尼亚医疗保健基金会、国家医疗保健管理研究所（NIHCM）、新英格兰州联盟系统组织、马萨诸塞州蓝十字蓝盾、哈佛朝圣者健康保健、凯撒基金会健康计划和 Partners HealthCare 提供给评估医疗保健干预措施价值的独立组织——临床与经济评论研究所（ICER）。ICER 的年度政策峰会由 Aetna、美国健康保险计划、Anthem、Allergan、Alnylam、AstraZeneca、Biogen、加州蓝盾、Cambia Health Services、CVS、Editas、Express Scripts、Genentech/Roche、GlaxoSmithKline、哈佛朝圣者、Health Care Service Corporation、Health Partners、Johnson & Johnson（Janssen）、Kaiser Permanente、LEO Pharma、Mallinckrodt、Merck、Novartis、National Pharmaceutical Council、Premera、Prime Therapeutics、Regeneron、Sanofi、Spark Therapeutics 和 United Healthcare 提供会费支持。Pearson 在 ICER 任职；Synnott 在撰写本报告时在 ICER 任职。Ollendorf、Campbell 和 McQueen 因参与本综述工作而从 ICER 获得资助。Ollendorf 还报告了与本综述无关的来自 Sarepta Therapeutics、DBV Technologies、EMD Serono、Gerson Lehman Group、CEA Registry Sponsors、Autolus、Analysis Group、Amgen、AbbVie、Cytokinetics、Aspen Institute/University of Southern California 和 University of Colorado 的咨询委员会、咨询和其他费用。
